In June 2017, the Hong Kong Stock Exchange (“HKEx”) initiated a holistic review of the Hong Kong listing regime to enhance its overall competitiveness against other major global listing venues, in particular to attract companies from emerging and innovative sectors. During this review, the HKEx identified the biotech industry and companies operating in the industry as a highly attractive pool of candidates for a Hong Kong listing. The HKEx recognized the fact that, in the U.S., biotech companies comprise the majority of companies seeking a listing in the early stage of the company’s development and the development of the company’s products. The HKEx also acknowledged that many biotech companies have legitimate capital markets needs ahead of having a revenue-generating commercial product or service. Why biotech companies? The HKEx believes that the regulation and oversight by internationally recognized regulatory agencies, such as the FDA, CFDA and EMA, and the stages involved in their approval process provide external validation and an indication as to the nature of biotech companies, and their development progress, in the absence of traditional financial indicators, such as revenue and profit.
Venantius (Ven) is one of the most recognized lawyers for Hong Kong capital markets deals due to his involvement in many of the early overseas B-Share and H-Share offerings by major PRC state-owned enterprises. He has more than 25 years of experience in a broad range of corporate and securities matters, including Hong Kong IPOs, dual listings, secondary offerings, corporate restructuring, and private and More ›
Vivian has more than 19 years of experience advising on a broad range of corporate transactions, including significant experience in Hong Kong capital markets offerings and China-focused M&A matters. Her practice focuses on initial public offerings and listings on the Hong Kong Stock Exchange, mergers and acquisitions, joint ventures, follow-on fund raising and compliance work. She regularly advises multinational corporations and Chinese enterprises (both More ›
Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet’s clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized by More ›
Dr. Jie Zhou is a partner in Morrison & Foerster’s Life Sciences Group. Her practice focuses on patent prosecution and counseling clients in the areas of biotechnology, pharmaceuticals, and cleantech. She has significant experience developing worldwide patent portfolios for companies of all sizes, from start-ups to multinational companies. She also advises clients on IP management and strategic portfolio planning. Because of her extensive experience in More ›